Cargando…
Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
SDZ PSC 833 (PSC 833) is a non-immunosuppressive analogue of cyclosporin A and is a potent modifier of P-glycoprotein (P-gp)-mediated multidrug resistance. The present study was undertaken to evaluate whether doxorubicin (DOX) pharmacokinetic and anti-tumour activity on P388- and P388/DOX-resistant...
Autores principales: | Colombo, T., Gonzalez Paz, O., D'Incalci, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074272/ https://www.ncbi.nlm.nih.gov/pubmed/8611397 |
Ejemplares similares
-
Restoration of doxorubicin responsiveness in doxorubicin-resistant P388 murine leukaemia cells.
por: Ramu, A., et al.
Publicado: (1984) -
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
por: van Asperen, J., et al.
Publicado: (1997) -
Inhibitory Effects of a Cyclosporin Derivative, SDZ PSC 833, on Transport of Doxorubicin and Vinblastine via Human P‐Glycoprotein
por: Kusunoki, Nobuya, et al.
Publicado: (1998) -
Modulation of Multidrug Resistance by SDZ PSC 833 in Leukemic and Solid‐tumor‐bearing Mouse Models
por: Watanabe, Toru, et al.
Publicado: (1996) -
L-histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia.
por: Warrington, R. C., et al.
Publicado: (1989)